Wells Fargo has revised its price target for Calumet (CLMT, Financial), decreasing it from $23 to $21 while maintaining an Overweight rating on the company's stock. According to the firm, the ongoing Path to MaxSAF project is progressing according to plan and is proving to be significantly more cost-effective than initially expected. Additionally, Wells Fargo highlights the potential benefits of asset sales, which could help mitigate any debt, bolstering the company's fiscal stability.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Calumet Inc (CLMT, Financial) is $20.00 with a high estimate of $33.00 and a low estimate of $12.00. The average target implies an upside of 42.86% from the current price of $14.00. More detailed estimate data can be found on the Calumet Inc (CLMT) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Calumet Inc's (CLMT, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Calumet Inc (CLMT, Financial) in one year is $13.49, suggesting a downside of 3.64% from the current price of $14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Calumet Inc (CLMT) Summary page.
